Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Galectin Therapeutics (GALT) stock drops 25% as NAVIGATE trial for belapectin in liver disorder MASH fails to meet main goal.

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Galectin Therapeutics (GALT) reported results from NAVIGATE clinical trial evaluating belapectin in patients with Metabolic ...

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic ...

Galectin Therapeutics Inc. Common Stock (GALT) stock saw a decline, ending the day at $1.04 which represents a decrease of $-0.96 or -48.00% from the prior close of $2. The stock opened at $1.18 and ...

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

Galectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate belapectin failed to reach the main goal in patients with liver ...

Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. The stock lost more than half its value, falling to about 91 cents ...

After hours: December 24 at 4:56:43 PM EST The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this ...

Galectin Therapeutics Inc. (GALT) has been on a downward spiral lately with significant selling pressure. After declining 31.8% over the past four weeks, the stock looks well positioned for a ...